Cysticercosis and taeniasis.
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: Neurocysticercosis is the main cause of adult-onset seizures in the developing world. Whether therapy with antiparasitic agents results in improved seizure control has been questioned because of the lack of adequate, controlled studies. METHODS: We conducted a double-blind, placebo-controlled trial in which 120 patients who had living cysticerci in the brain and seizures treated with antiepileptic drugs were randomly assigned to receive either 800 mg of albendazole per day and 6 mg of dexamethasone per day for 10 days (60 patients) or two placebos (60 patients). The patients were followed for 30 months or until they had been seizure-free for 6 months after the doses of the antiepileptic drugs had been tapered. The efficacy of treatment was measured as the decrease in the number of seizures after treatment. RESULTS: In the albendazole group, there was a 46 percent reduction in the number of seizures (95 percent confidence interval, -74 to 83 percent) during months 2 to 30 after treatment. This reduction, which was not statistically significant, was composed of a nonsignificant reduction of 41 percent in the number of partial seizures (95 percent confidence interval, -124 to 84 percent) and a significant 67 percent reduction in the number of seizures with generalization (95 percent confidence interval, 20 to 86 percent). Most of the difference in the number of partial seizures was attributable to a few patients who had many seizures during follow-up. The proportions of patients who had partial seizures during follow-up were similar in the two groups (19 of 57 in the albendazole group and 16 of 59 in the placebo group), but the patients in the placebo group had a greater tendency to have seizures with generalization (22 of 59, vs. 13 of 57 in the albendazole group; risk ratio, 1.63; 95 percent confidence interval, 0.91 to 2.92). More of the intracranial cystic lesions resolved in the albendazole group than in the placebo group. With the sole exception of abdominal pain, side effects did not differ significantly between the two groups. CONCLUSIONS: In patients with seizures due to viable parenchymal cysts, antiparasitic therapy decreases the burden of parasites and is safe and effective, at least in reducing the number of seizures with generalization.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Methyl [5-([4-(2-pyridinyl)-1-piprazinyl] carbonyl)-1H benzimidazole-2-yl] carbamate, a broad spectrum anthelmintic, was tested against Cysticercus fasciolaris in rats and the cysticercoids of Hymenolepis nana in beetles. A dose of 50 mg kg-1, given intraperitoneally (i.p.) to infected rats on 10 alternate days, was found most effective, killing all mature cysticerci. The same dose, given on each of five days, either from the fifth day prior to infection or the sixth day following infection, fully arrested the establishment of cysticerci. A single prophylatic dose of 500 mg kg-1, given intramuscularly (i.m.), protected rats against challenge with Taenia taeniaeformis eggs for 10 days. The test compound, mebendazole and praziquantel were all totally ineffective against mature cysticercoids in grain beetles but, of the beetles fed the drugs in flour, 66.3%, 50% and 83.8%, respectively, failed to support the development of immature cysticercoids. The effective cysticidal action of the compound makes it a candidate medical anthelmintic.
Explore the source record for details and available documents.
The introduction of the immunoblot into the repertoire of serodiagnostic assays began with the confirmatory testing of human immunodeficiency virus (HIV) antibodies. The difficulty of producing immunoblot strips and the complexity of the time-consuming serum/conjugate incubation steps deterred more widespread use of the immunoblot. Using the simple Schleicher * Schuell AccutranTM system, can greatly reduce the complexity for strip production and incubation. By simply increasing reagent concentrations, we can reduce incubation times for sera and conjugates (enzyme-labeled second antibodies) to 5 minutes from the usual 1 hour or overnight incubation times. The resulting RAPID BLOT shows no reduction of sensitivity or specificity.